WINTAC LIMITED DELISTED SHARE
WINTAC LIMITED was established as an offspring of Bangalore Pharmaceuticals and Research Laboratories Private Limited under the name of RECON LIMITED. In 2001, the name of the company was changed to Wintac Limited. The Company is engaged in the business of manufacturing of goods and all its other activities revolve around this business. The company’s range of specialties includes Large and small volume injectable and Ophthalmic solutions.
The delisting open offer for shares of WINTEC LIMITED was successful as per Regulation 17 of the Delisting Regulations at an exit price of `350 per share under the Reverse Book Building Process. The BSE vide its’ notice no. 20201211-16 dated December 11, 2020, communicated that the trading in the Equity Shares of the Company WINTEC LIMITED (Scrip Code: 524758) will be discontinued from December 18, 2020, and the scrip will be delisted from Exchange records with effect from December 28, 2020.
Wintac Limited provides outsourcing for sterile pharmaceutical products and Ophthalmic Solutions. Wintac Limited takes care of its customers from formulation development to commercial manufacturing.
The product range of the company includes a wide range of ophthalmic preparations and Injectables of Large and small volume parenteral.
The equity shares of the company have been delisted from the Bombay Stock Exchange of India on December 28, 2020.
INCORPORATION DETAILS
CIN | L85110KA1990PLC011166 |
Registration Date | 23 August 1990 |
Category/Sub-category of the Company | Public Limited |
Address of the Registered office and contact details | 54/1, BOODHIHAL, NELAMANGALA, BENGALURU - 562123. PH:- 080-67086500 |
Name, Address, and Contact Details of Registrar and Transfer Agent, if any | CANBANK COMPUTER SERVICES LTD., NO.218, J.P.ROYALE, II MAIN, SAMPIGE ROAD, MALLESWARAM, BANGALORE - 560003. PH: 080-23469661/9662 |
PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY
Name and Description of main products/services | NIC Code of the product/service | % to the total turnover of the Company |
Formulation Sales | 99532693 | 80.65% |
Manufacturing Charges | 99532693 | 0.21% |
Formulation Development | 99839390 | 19.14% |
BOARD OF DIRECTORS
Shri S.T.R. Mady (Chairman)
Shri S. Jayaprakash Mady (Director)
Shri R.A. Thirumoorti (Director)
Dr. K. Paranjothy (Director)
Ms. S. Nanthitha (Additional Director)
Mr. Arshad Kagalwalla (Additional Director)
Shri Sunil B. Gundewar (Manager & C.O.O)
Shri B.P. Thyagaraj V.P. (Finance) & Secretary
PARTICULAR'S OF SUBSIDIARY AND ASSOCIATE COMPANIES
WINTAC LIMITED does not have any subsidiary or associate company.
WINTAC LIMITED DELISTED SHARE DETAILS
SHAREHOLDING PATTERN
(As of 31-03-2020)
S. No. | Shareholders’ Name | Number of shares | % of total Shares of the company |
1 | VEEGO Pharma LLC (Promoter) | 92,40,346 | 92.18% |
2 | Public Shareholding | 7,83,896 | 7.82% |
| Total | 1,00,24,242 | 100.00% |
INDUSTRY OUTLOOK
Indian Pharmaceutical market ranks as 3rd largest in the world in terms of volume and 14th largest in terms of value. Healthcare has become one of the largest sectors of the Indian economy, in terms of both employment and revenue. India is known as the Pharmacy of the world and is the largest provider of generic drugs at a global level. The pharmaceutical industry of India supplies over 50% of the global demand for various vaccines, 40% of generic demands in the USA, and 25% of all the medicines in the United Kingdom. Excellent Research & Development, low cost of labor, availability of management and technical personnel, and local equipment availability has helped India to manufacture pharma products at a very low cost.
The Indian healthcare market may see a 3 fold jump in terms of value to reach US$ 372 billion by FY 2022. The growth can be attributed to rising income, greater health awareness, increased precedence of lifestyle disease, and Indian prominence in making medicinal products for the treatment of COVID 19. India aims to achieve vaccination for COVID-19 of 30 Crore people in the next few months.
Export of Pharmaceuticals products from India stood at US$ 16.8 billion in FY 2020 and US$ 2.07 billion in the month of October 2020. In the first 3 quarters of FY 2021, India exported pharmaceuticals worth US$ 15.86 billion. India supplied around 45 tons and 400 million tablets of hydroxychloroquine to around 114 countries globally to treat the covid patients in the initial stage of the covid-19 pandemic. Exports in FY 2021 of Indian pharma products are expected to cross US$ 24 billion, increasing by over 16% when compared to FY 2020.
After the onset of COVID 19, the Indian pharmaceutical sector became the busiest sector in the Indian economy. The pandemic proved to be a boon in disguise for the Indian pharmaceutical sector.
PROFIT & LOSS STATEMENT OF WINTAC LIMITED (In Rs. Lakhs)
PARTICULARS | 2020 | 2019 | 2018 | 2017 |
Revenue from Operations | 8,511.01 | 7,192.01 | 4,479.70 | 3,489.81 |
EBITDA | 276.70 | 337.55 | -597.30 | -733.59 |
Finance Cost | 191.27 | 93.38 | 89.92 | 99.65 |
Depreciation | 723.76 | 418.13 | 354.64 | 363.18 |
Other Income | 275.97 | 194.95 | 71.88 | 110.50 |
Profit/Loss before Tax | -362.36 | 20.99 | -969.98 | -1,085.91 |
Exceptional items | 0.00 | 0.00 | 0.00 | 118.87 |
Total Tax | -56.14 | 10.08 | 9.24 | -121.03 |
Profit After Tax (PAT) | -306.22 | 10.91 | -979.22 | -846.01 |
EPS | -3.05 | 0.11 | -9.77 | -8.44 |
BALANCE SHEET OF WINTAC LIMITED (In Rs. Lakhs)
PARTICULARS | 31st March 2020 | 31st March 2019 |
ASSETS | ||
NON CURRENT ASSETS | ||
Tangible assets | 10,747.66 | 9,085.09 |
Intangible assets | 48.30 | 49.30 |
Financial assets | 47.03 | 441.87 |
Tax assets (net) | 724.91 | 643.33 |
Other non-current assets | 127.84 | 195.62 |
TOTAL NON CURRENT ASSETS | 11,695.74 | 10,415.21 |
CURRENT ASSETS | ||
Inventories | 2,532.42 | 1,944.62 |
Trade Receivables | 309.71 | 191.82 |
Cash and cash equivalents | 134.93 | 6.23 |
Financial assets | 100.90 | 192.53 |
Other current assets | 1,375.68 | 860.62 |
TOTAL CURRENT ASSETS | 4,453.64 | 3,195.82 |
TOTAL ASSETS | 16,149.38 | 13,611.03 |
EQUITY | ||
Share capital | 1,002.42 | 1,002.42 |
Reserves and surplus | -1,819.26 | -1,440.59 |
TOTAL EQUITY | -816.84 | -438.17 |
NON CURRENT LIABILITIES | ||
Borrowings | 2,128.15 | 1,378.31 |
Other non-current liabilities | 9.88 | 13.19 |
Long Term Provision | 345.42 | 111.83 |
TOTAL NON CURRENT LIABILITIES | 2,483.45 | 1,503.33 |
CURRENT LIABILITIES | ||
Short-term borrowings | 238.15 | 5,016.97 |
Trade payables | 1,319.90 | 1,264.74 |
Other Current Liabilities | 12,844.99 | 6,148.65 |
Short Term Provision | 79.73 | 115.51 |
TOTAL CURRENT LIABILITIES | 14,482.77 | 12,545.87 |
TOTAL LIABILITIES | 16,966.22 | 14,049.20 |
TOTAL EQUITY AND LIABILITIES | 16,149.38 | 13,611.03 |
DIVIDEND HISTORY
Particulars | 2020 | 2019 | 2018 |
Dividend (final + interim) (In Rs.) | Nil | Nil | Nil |
Retained Earnings (Consolidated) (In Rs. Lakhs) | -7,328.29 | -6,949.62 | -6,933.62 |
PERFORMANCE OF THE COMPANY
Revenue from Operations of the company increased by 18.34% from Rs. 7,192.01 lakhs in FY 2019 to Rs. 8,511.01 lakhs in FY 2020. The Company earns 85.31% (Previous Year 83.97% from two customers) of revenue from operations has been earned from a single customer.
EBITDA of the company decreased by 18.03% from Rs. 337.55 lakhs in FY 2019 to Rs. 276.70 lakhs in FY 2020. EBITDA margins decreased from 4.69% in FY 2019 to 3.25% in FY 2020.
The company incurred a loss of Rs. 306.22 lakhs in FY 2020, as against a profit of Rs. 10.91 lakhs.
The current ratio of the company as of 31st March 2020 was 0.30.
The company’s net worth is negative and is Rs. -816.84 lakhs. Moreover has a debt of Rs. 2,366.30 lakhs as of 31st March 2020.
The company has not given any dividends for the past three years.
Powered by Froala Editor
